In early 2024, the bird influenza that had been spreading across the globe for nearly three decades did something wholly ...

Hello and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host, Zacks Small Cap Research, we're very pleased you joined us for our quarterly ...

How should continental vaccine manufacturers handle complex dynamics of supply and demand? ANALYSIS | The African Union has ...

Researchers at Rutgers University have created a new antiviral drug for COVID-19 that could be safer and more effective than Paxlovid, the current leading treatment. The new drug, called Jun13296, may ...

Clear Blue Technologies International Inc. ("Clear Blue" or the "Company"), a leader in Smart Power solutions for the telecom and IoT sectors, is pleased to announce the successful completion of a ...

Each year, seasonal flu sickens about 1 billion people worldwide and causes approximately 290,000 to 650,000 respiratory ...

As schools reopen, the Korea Disease Control and Prevention Agency (KDCA) reports an uptick in flu cases following a recent ...

Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral ...

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...

Researchers conducted a study to determine the vaccine effectiveness of the 2023 to 2024 influenza vaccine across age groups and by virus type and subtype.

In today's interconnected world, infectious diseases pose an escalating threat, as demonstrated by the coronavirus pandemic ...

One year after the first Influenza A case was confirmed in a Texas dairy herd, state veterinarians are still trying to ...